BiotechTube

escitalopram + escitalopram

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Major Depressive Disorder

Conditions

Major Depressive Disorder

Trial Timeline

May 1, 2012 → Dec 1, 2016

NCT ID
NCT01594866

About escitalopram + escitalopram

escitalopram + escitalopram is a approved stage product being developed by Lundbeck for Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01594866. Target conditions include Major Depressive Disorder.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT01594866ApprovedCompleted
NCT02480400Pre-clinicalCompleted

Competing Products

20 competing products in Major Depressive Disorder

See all competitors
ProductCompanyStageHype Score
Duloxetine HydrochlorideEli LillyPre-clinical
23
LY2216684Eli LillyPhase 1
33
LY2216684Eli LillyPhase 1
33
DuloxetineEli LillyPhase 3
77
LY2216684 + DigoxinEli LillyPhase 1
33
Duloxetine + ParoxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
52
FK949EAstellas PharmaPhase 1
33
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
52
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
Mirtazapine TabletsSun PharmaceuticalApproved
85
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Pramipexole ER + EscitalopramCiplaPhase 2
52
LY2216684 + SertralineEli LillyPhase 1
33
LY2216684 + Placebo + LorazepamEli LillyPhase 1
33
LY2216684 + SSRIEli LillyPhase 3
77

Other Products from Lundbeck

VortioxetineApproved
82
memantine + memantine + placeboApproved
82
BrexpiprazoleApproved
82
losartan (drug)Approved
82
vigabatrinApproved
82